The microbiome-focused group has some explaining to do.
The Swiss group has likely been paying attention to industry developments as BCMA and CD40 go out, while Covid-19 and Tim-3 move up.
An FDA advisory committee refuses to overlook the potential dangers of roxadustat, Fibrogen's novel anaemia pill, leaving partner Astrazeneca with a difficult…
GLPG3970 is biologically inert in ulcerative colitis and rheumatoid arthritis, so Galapagos’s search for something better goes on.
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
Upon review Pepaxto beats Pomalyst on progression-free survival, but new overall survival data trigger clinical hold and threaten the programme.